Exhibit 99.2 Amedisys Fourth Quarter 2021 Earnings Call Supplemental Slides 1 1 th, February 24 2022

Forward-looking statements This presentation may include forward-looking statements as defined by the Private www.amedisys.com Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a NASDAQ: AMED variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as We encourage everyone to visit the a prediction of future events. Investors Section of our website at Additional information regarding factors that could cause actual results to differ materially www.amedisys.com, where we have posted additional important from those discussed in any forward-looking statements are described in reports and information such as press releases, registration statements we file with the SEC, including our Annual Report on Form 10-K profiles concerning our business and and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, clinical operations and control copies of which are available on the Amedisys internet website http://www.amedisys.com processes, and SEC filings. or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. 2

A Look Back FY 2021 Accomplishments Operational Excellence and Driving Growth Employer of Choice Clinical Distinction Efficiency• Grew Home Health same • Ended the year with overall • Maintained at least 95% of store total admissions • Grew EBITDA by 10% from voluntary turnover of all Home Health care centers +6% and Hospice same $273.5M in 2020 to $299.6M 19.4% (FY’21) achieving 4.0+ Quality of store total admissions in 2021 Patient Care star score +2% • While the industry is reporting • Expanded consolidated • Acquired four CONs and VNA • Outperformed industry record increases in nursing EBITDA margin 40 bps to (Home Health in Omaha, NE) on all hospice item set (HIS) turnover; in 2021, we reduced 13.6% (FY’21) despite • Acquired Contessa Health quality metrics our nursing turnover to continuing impacts from (closed in August 2021) 26.8% from 29.5% in 2020, COVID-19• Contessa subsequently a 9% YoY reduction signed new JV partnerships • Delivered $189M in cash with Henry Ford Health 3 flow from operations Plan and Penn State Health

Our Key Areas of Focus Strategic areas of focus and progress made during Q4’21 2 5 3 4 6 1 Recruiting / Clinical Organic Capacity and Regulatory M&A Retention Initiatives Growth Productivity • Signed a new • Home Health*: • Targeting industry • Quality: Amedisys • Focusing on 2021 Hospital at Home Total same store leading employee Jan’22 release optimizing RN / Reimbursement STARS score of 4.33 JV with Penn State admissions +2%, retention amongst LPN & PT / PTA (SHP: 4.5 STARS) Health (11/10/21)• Final Home Health Total same store all employee staffing ratios. volume +2% categories industry rule net • Signed the • 95% of care centers • Current LPN +1.9% increase acquisition of • Hospice: Total • Q4’21 Voluntary at 4+ Stars based on Ratio: 49.0% • Final Hospice industry internal calculation Evolution Health rule net +2.4% same store Turnover 21.5% (vs. 47.5% in on 2/1/22 increase (effective Admissions -1%, 4Q’20) ADC -4%• 533 Hospice BD • 37 Amedisys care expanding our 10/1/20) footprint in TX, OK FTE’s as of YE’21 centers rated at 5 • Current PTA and OH (15 care • Personal Care: PC (+52 over PY) Stars in the Jan’22 Ratio: 52.9% (vs. 2022 Release centers) – expected Reimbursement Network drove 50.9% in 4Q’20) to close summer of ~$522K in revenue • 877 Home Health to Home Health and BD FTE’s as of • Hospice quality – 2022• Final Home Health Hospice via care YE’21 (+37 over PY) outperforming industry rule net • Signed Assisted coordination industry average in +3.2% increase Care Home Health all hospice item set • Final Hospice industry (HIS) categories (2 locations in rule net +2.0% North Carolina) on increase (effective 2/21/22 10/1/21) • Sequestration suspension extended until 6/30/22. Full 2% for three months reduced to 1% for remaining three months 4 *Note: Home Health same store volume is defined as admissions plus recertifications

(1) Highlights and Summary Financial Results (Adjusted): 4Q 2021 Home Health total same store volume +2%, total same store admissions +2%; Hospice same store admissions -1%; Margin pressure driven by Hospice ADC decline & labor costs Adjusted Financial Results Amedisys Amedisys Amedisys Consolidated Balance Sheet & Cash Flow $ in Millions, except EPS 4Q20 4Q21 FY 2020 FY 2021 Consolidated Consolidated Home Health 329.4 337.3 1,249.2 1 ,353.8 • Revenue Growth: +2% • Net debt: $403.8M Hospice 203.9 204.9 750.1 785.3 Personal Care 17.4 1 5.1 72.2 65.0 • EBITDA: $65M (-17%, ex. • Net Leverage ratio: 1.3x High Acuity Care - 2.0 - 3.5 Contessa -10%) • Revolver availability: $522.5M Total Revenue $ 550.7 $ 55 9.3 $ 2 ,071.5 $ 2,207.6 • EBITDA Margin: 11.6% (ex. • CFFO: $5.2M Gross Margin % 45.5% 44.1% 44.6% 45.1% Contessa: 12.6%) (4) Adjusted EBITDA 78.1 64.8 273.5 299.6• Free cash flow : $1.2M • EPS: $1.18 (-21%) 14.2% 11.6% 13.2% 13.6% • DSO: 43.2 (vs. Q4’20 of 40.2 and Adjusted EPS $1.49 $1.18 $6.11 $5.95 down 0.3 days since Q3) (4) Free cash flow $60.6 $1.2 $273.5 $174.3 Hospice Home Health Personal Care High Acuity Care (2)(3) (3) Same Store : Same Store Volume : Growth Metrics: Growth Metrics: • Total Volume: +2% • Billable hours/quarter: -24% • Admissions: -1% • Total Admissions: 286 • Total Admissions: +2% • Clients served: -22% • ADC: -4% • Number of JV’s: 8 Other Statistics: Other Statistics: Other Statistics: (5) Other Statistics: • Revenue per Episode : $2,951 • Revenue per hour: +15% • Revenue per Day: $168.24 • Patient Satisfaction: 97% (+1.5%) • Cost per hour: +17% (+4.7%) • Total Cost per Visit: $106.67 • Cost per day: $90.23 (+10.8%) (+5.9%) 1. The financial results for the three-month periods and years ended December 31, 2020 and December 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Same Store volume – Includes admissions and recertifications. 3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 5 4. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments. Q4’20 free cash flow includes payroll tax deferrals. 5. Medicare sequestration suspended 5/1/20.

Our Revenue Sources: 4Q’21 Amedisys Consolidated Revenue Home Health Revenue Hospice Revenue 0.4% 5.3% 2.7% 19.1% 36.6% 12.7% 68.2% 60.3% 94.7% Home Health Hospice Medicare FFS Private Episodic Per Visit Medicare FFS Private Personal Care High Acuity Care • Home Health: 331 care centers; 34 states & D.C.• Medicare FFS: Reimbursed over a 30-day Hospice Per Day Reimbursement: • Hospice: 175 care centers; 34 states period of care • Routine Care: Patient at home with • Personal Care: 14 care centers; 3 states• Private Episodic: MA and Commercial plans symptoms controlled ~97% of the Hospice • High Acuity Care: 8 Joint Ventures; 6 states; 24 who reimburse us over a 30-day period of care, care AMED provides, in line with overall referring hospitals majority of which range from 95% - 100% of hospice industry provision of care • Total AMED: 528 care centers; 38 states and Medicare rates• Continuous Care: Patient at home with D.C.• Per Visit: Managed care, Medicaid and private uncontrolled symptoms payors reimbursing us per visit performed• Inpatient Care: Patient in facility with uncontrolled symptoms • Respite Care: Patient at facility with symptoms controlled 6 6

(1) Home Health and Hospice Segment (Adjusted) – 4Q 2021 Home Health total volume growth +2%; Hospice Admit Growth -1% HOSPICE HOME HEALTH Year Ended Year Ended $ in Millions 4Q20 4Q21 2020 2021 $ in Millions 4Q20 4Q21 2020 2021 Medicare 193.5 193.9 710.0 743.6 Medicare 228.3 230.1 847.3 914.5 Non-Medicare 10.4 11.0 40.1 41.7 Non-Medicare 101.1 107.2 401.9 439.3 Hospice Revenue $203.9 $204.9 $750.1 $785.3 Home Health Revenue $329.4 $337.3 $1,249.2 $1,353.8 Gross Margin % 44.2% 43.8% 43.5% 45.1% Gross Margin % 49.3% 46.4% 48.3% 46.9% (2) (2) Pre-Corporate EBITDA $65.2 $62.9 $236.7 $281.6 Pre-Corporate EBITDA $52.7 $41.0 $187.4 $169.7 19.8% 18.7% 19.0% 20.8% 25.8% 20.0% 25.0% 21.6% Operating Statistics Operating Statistics Admit growth - same store (4 ) 15% -1% 6% 2% Same Store Growth (3 )(4 ) ADC growth - same store (4 ) 0% -4% 1% -4% Total Volume 5% 2% 2% 5% Total Admissions 6% 2% 1% 6% ADC 13,793 13,237 13,081 13,271 Avg. discharge length of stay 102 90 99 94 Medicare Revenue per Episode (5 ) $2,906 $2,951 $ 2,836 $ 2 ,959 Medicare Recert Rate 34.5% 35.1% 36.3% 35.1% Revenue per day (net) $160.72 $168.24 $156.69 $162.12 Cost per day $81.45 $90.23 $81.02 $86.15 Total Cost per visit $100.69 $106.67 $95.59 $101.46 Home Health Highlights Hospice Highlights • Revenue per Episode up 1.5% (+1.9% rate increase effective • Net revenue per day +4.7% (primarily due to +2.0% Hospice rate 1/1/2021) update effective 10/1/2021 and favorable cap adjustments) • Y/Y CPV up $5.98 (+5.9%, primarily due to raises, new hire pay, clinician bonuses, wage inflation and health insurance) • Visits per Episode decreased 0.3 1. The financial results for the three-month periods and years ended December 31, 2020 and December 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Pre-Corporate EBITDA does not include any corporate G&A expenses. 3. Same Store information represents the percent change in volume or admissions for the period as a percent of the volume or admissions of the prior period. 4. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 7 5. Average Medicare revenue per completed episode reflects the transition to PDGM effective Jan. 1, 2020 and the suspension of sequestration effective May 1, 2020.

(1,2) General & Administrative Expenses – Adjusted Impacted by COVID-19, acquisitions and investments to drive volume growth 4Q20 1Q21 2Q21 3Q21 4Q21 $ in Millions 4Q20 1Q21 2Q21 3Q21 4Q21 Salary and Benefits 25.0 23.4 22.0 22.1 21.7 Home Health Segment - Total 80.5 80.0 81.3 82.4 84.7 Other 13.2 12.7 11.6 12.8 10.4 % of HH Revenue 24.4% 24.3% 23.3% 24.3% 25.1% Corp. G&A Subtotal 38.2 36.1 33.6 34.9 32.1 Non-cash comp 4.6 5.3 4.5 2.8 4.0 Hospice Segment - Total 47.9 46.3 48.4 49.5 54.0 Adjusted Corporate G&A 42.8 41.4 38.1 37.7 36.1 % of HSP Revenue 23.5% 24.2% 25.3% 25.1% 26.4% Total G&A as a Percent of Revenue Personal Care Segment - Total 3.0 3.1 3.1 2.6 2.4 34.0% 32.8% % of PC Revenue 17.2% 18.2% 18.1% 16.5% 15.7% 31.8% 31.8% 31.6% 32.0% High Acuity Care Segment - Total - - - 3.8 6.2 30.7% % of HAC Revenue -% -% -% 255.2% 305.7% 30.0% Total Corporate Expenses 42.8 41.4 38.1 37.7 36.1 % of Total Revenue 7.8% 7.7% 6.8% 6.8% 6.5% 28.0% 4Q20 1Q21 2Q21 3Q21 4Q21 Total 174.2 170.8 170.9 176.0 183.4 G&A as a Percent of Revenue % of Total Revenue 31.6% 31.8% 30.7% 31.8% 32.8% Notes: • Year over year total G&A as a percentage of revenue increased 120 basis points ($9 million); 20 basis point ($3 million) increase excluding Contessa • Increases related to the Contessa acquisition, raises, the addition of resources to support growth, higher travel and training spend and higher health insurance costs were offset by lower incentive compensation costs • Total G&A as a percentage of revenue increased 100 bps sequentially 1. The financial results for the three-month periods ended December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 8 2. Adjusted G&A expenses do not include depreciation and amortization.

Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted YOY Total CPV impacted by planned wage increases, wage inflation, new hire pay and higher health insurance costs. Contractor costs down slightly year over year as utilization has stabilized Components 4Q’20 3Q’21 4Q’21 YoY Variance Detail Initiatives Salaries $66.09 $67.58 $69.73 $3.64 YoY increase (+5.5%) due to higher Staffing mix optimization, fixed new hire pay (+1.9%), planned productivity and scheduling wage increases, wage inflation and improvement initiatives in place clinician bonuses to help overcome salary increases Sequential increase due to the same drivers, including one additional month of raises Contractors $5.08 $4.96 $4.93 ($0.15) YoY and Sequential variances Focused efforts on filling minimal due to relatively consistent positions with full-time clinicians utilization Benefits $12.98 $13.16 $14.52 $1.54 YoY increase due to the impact of Focus on cost containment and COVID-19 on health insurance costs spend optimization with specific (lower utilization in prior year) focus on high-cost claims Sequential increase due to the seasonality of claims Transportation & Supplies $7.16 $7.28 $7.10 ($0.06) *Visiting Clinician CPV $91.31 $92.98 $96.28 $4.97 Clinical Managers $9.38 $9.85 $10.39 $1.01 Fixed cost associated with non- Unit cost reduced as volume visiting clinicians increases YoY increase driven by additional staff and planned wage increases Total CPV $100.69 $102.83 $106.67 $5.98 *Note: Direct comparison with industry competitors CPV calculation Cost Per Visit (CPV) $96.28 $91.31 $92.98 $100.00 $75.00 $50.00 $25.00 4Q20 3Q21 4Q21 9 Salaries Contractors Benefits Transportation

Driving Top Line Growth Home Health total volume, Hospice admissions and ADC, as well as Personal Care billable hours lagging due to prolonged COVID-19 impacts related to the Omicron variant (staffing challenges, increase in clinician quarantine and increase in hospice discharge rate) Home Health Hospice Personal Care Total Volume Growth Total Hours / Quarter 12% 150,000 15.0% 1,000,000 14,500 20% 12.0% 15% 15% 5% 14,000 800,000 6% 9.0% 10% 13,500 600,000 100,000 6.0% 1% 2% 5% 5% 2% 1% 13,000 0% 3.0% 400,000 0% -3% -1% 0.0% 12,500 -4% -4% -5% -5% 200,000 50,000 -3.0% 12,000 -10% 4Q20 1Q21 2Q21 3Q21 4Q21 0 Q420 Q121 Q221 Q321 4Q21 4Q20 1Q21 2Q21 3Q21 4Q21 Volume YoY Same Store Growth ADC Admits Billable Hours SS ADC Growth SS Admit Growth 10

Industry Leading Quality Scores Quality of Patient Care (QPC) Patient Satisfaction (PS) JAN 20 APR 20 OCT 20 JAN 22 JAN 20 APR 20 OCT 20 JAN 20 Metric Metric Release Release Release Release Release Release Release Release Quality of Patient 4.27 4.26 4.33 3.71 3.79 4.28 4.33 3.60 Patient Care Satisfaction Star Entities at 4+ Performance 86% 86% 92% 92% +6% +6% +7% +3% Stars Over Industry QPC Industry Performance PS Industry Performance 4.50 4.50 CMS 4.00 4.00 Blind CMS Period Blind Period 3.50 3.50 3.00 3.00 Amedisys QPC Industry Avg QPC Top Competitor Amedisys PS Score PS Industry Avg PS Top Competitor • Amedisys maintains a 4-Star average in the Jan 2022 HHC Release with 92% of our providers (representing 95% of care centers) at 4+ Stars and 61% of our providers (representing 67% of care centers) at 4.5+ Stars. •25 Amedisys providers (representing 37 care centers) rated at 5 Stars. 11 Notes: (1) CMS did not provide QPC Star and HH-CAHPS performance releases in 2021 due to COVID-19 PHE. (2) Jan 2022 QPC Star Release performance period = 7/1/2020 – 3/31/2021 (CY 2019 for ACH). (3) Jan 2022 HH-CAHPS Release performance period = 7/1/2020 – 6/30/2021.

Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Notes: Included in the above analysis are active care centers. Acquired locations were only included if their acquisition date was before the start of the reporting window. Above excludes Asana, Aseracare, and CCH acquisitions. 12 * Hospice Visits When Death is Imminent, Measure 1 is referencing discharges from Jan 2019 through Dec 2019

Debt and Liquidity Metrics Net leverage ~1.3x As of: Outstanding Debt 12/31/21 Outstanding Revolver - Outstanding Term Loan 447.2 Promissory Notes 0.8 Finance Leases 1.6 Total Debt Outstanding 449.6 Less: Deferred Debt Issuance Costs (4.5) Total Debt - Balance Sheet 445.1 Total Debt Outstanding 449.6 Less Cash (45.8) (1) Net Debt 403.8 (2) Leverage Ratio (net) 1.3 As of: Credit Facility 12/31/21 Term Loan 450.0 Revolver Size 550.0 Borrowing Capacity 1,000.0 Revolver Size 5 50.0 Outstanding Revolver - Letters of Credit ( 27.5) Available Revolver 522.5 Plus Cash 45.8 (3) Total Liquidity 568.3 1. Net debt defined as total debt outstanding ($449.6M) less cash ($45.8M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($299.6M). 3. Liquidity defined as the sum of cash balance and available revolving line of credit. 13

(1) Cash Flow Statement Highlights 2020 includes benefit of payroll tax deferral (COVID-19 relief). Total payroll tax deferral of ~$55M (half paid in December 2021; remainder due in December 2022). $ in Millions 4Q20 1Q21 2Q21 3Q21 4Q21 GAAP Net Income 45.6 5 0.3 80.6 4 5.2 34.0 Changes in working capital 34.5 (1 8.3 ) (9.1 ) (7 .0) (2 7 .1 ) Depreciation and amortization 8.8 7 .6 6.7 7 .5 9.1 Non-cash compensation, includes 401 (k) match expense 7 .0 7 .3 6.2 4.4 5.9 Deferred incom e taxes (23.8) 7 .4 1 5.3 1 2.0 9.9 Other (6.2) (0.3 ) (31 .7 ) (0.3) (26.6) Cash flow from operations 65.9 54.0 68.0 61.8 5.2 Capital expenditures - routine (2.4) (1 .6) (1 .0) (2.2) (0.7 ) Required debt repay ments (2.9) (2.7 ) (2.7 ) (0.5) (3 .3) Free cash flow 60.6 49.7 64.3 59.1 1.2 Capital Deployment Acquisitions 0.8 - (2.5) (262.4) (5.1 ) Share Repurchases - (7 2.9) (1 .2) (1 0.8) (1 5.0) Total 0.8 (72.9) ( 3.7) (273.2) (20.1) 14 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.

(1) Income Statement Adjustments $000s Income Statement Line Item 4Q20 1Q21 2Q21 3Q21 4Q21 Revenue Contingency accrual Net Serv ice Rev enue $ - $ - $ (6,541 ) $ - $ - Other Operating Income CARES Act & State COVID-1 9 grants Other Operating Income ( 6,7 80) (8,7 01 ) (4,603) 4 - Cost of Service COVID-1 9 costs Cost of Serv ice, Excluding Depreciation & Amortization 6,568 8,480 4,464 3,51 3 4,323 G&A Acquisition and integration costs G&A, Salaries and benefits 507 1 96 51 0 1 ,07 1 41 9 COVID-1 9 costs G&A, Salaries and benefits 45 25 9 60 9 Acquisition and integration costs G&A, Other 7 27 1 ,003 1 ,7 83 1 ,686 891 COVID-1 9 costs G&A, Other 1 32 1 92 1 51 1 39 1 31 Pre-acquisition legal settlement G&A, Other - - 1 ,825 - - Other Items Asset impairment (acquired names) Asset impairment 4,1 52 - - - - Interest component of certain items Interest expense 464 51 7 469 4 51 4 51 Other (income) expense, net (2) Total other (expense) income, net - - (31 ,07 7 ) (66) 1 88 Total $ 5,815 $ 1,712 $ (33,010) $ 6,858 $ 6,412 EPS Impact $ 0 .13 $ 0 .04 $ (0.74) $ 0.17 $ 0.15 1. The financial results for the three-month periods ended December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 15 2. Other (income) expense, net includes ~$31.1 million gain on Medalogix equity method investment for the three-month period ended June 30, 2021.

2022 Guidance 16

Amedisys 2022 Preliminary Guidance Revenue, EBITDA and EPS guidance ranges for FY 2022 ($M except for EPS) AMED Core High Acuity Care Total Performance AMED Adjusted Revenue $2,274 - $2,309 $56 $2,330 - $2,365 Adjusted $301 - $311 ($26) $275 - $285 EBITDA Adjusted EPS $5.88 - $6.10 ($0.65) $5.23 - $5.45 2022 EBITDA Impacts:• Additional impact from • Incentive Comp: ~$16M Contessa related to resources • Incremental Contessa: ~$17M needed to service expanded • Omicron impact: ~$7M Hospital @ Home JV pipeline, • De Novos: ~$5M along with resources allocated • Investments: ~$3M to new Palliative Care business Total: ~$48M line. Guidance Disclaimer COVID-19 has impacted the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa. We are basing our guidance on our current operating environment. COVID-19 continues to evolve in both the disease itself as well as disruptions to the healthcare systems and the economy. Any future regulations or government interventions, spike in clinicians and BD staff on quarantine, staffing shortages due to current and proposed federal, state and local vaccine mandates, reduction in elective procedures, change in patient behavior and further decline in senior living occupancy could impact our ability to achieve this guidance. 17

2022 Guidance Considerations EBITDA impacted by continued Hospice length of stay pressures, incremental Contessa investments, incentive compensation and costs related to Omicron Amedisys Home Health Hospice Personal Care Consolidated • Tax rate ~27% • Total same store • Total same store • Total billable hours admission growth: ~5% admission growth: ~13% growth: -3% • Cash tax rate ~19% • Continued investment in • Addition of business • Personal Care Network to • Diluted share count ~33.2 business development development resources to drive ~$2M revenue to million shares staffing to support growth support ADC growth ~ $4 Home Health and • Capital Expenditures ~$7-$9 ~$4 million million Hospice combined million • Continued focus on Quality of • +2.0% rate increase • Salary increase ~2% - 3% High Acuity Care (Stars and Acute Care • Benefits increase ~11% (8% Hospitalization rates) Care growth / headcount, 3% pricing • +3.2% rate increase / claims costs) • 5 new Joint Venture arrangements in 2022 • Overall ~$8 million investment in business • $56M Revenue development resources • ($26M) EBITDA impact • Excludes future acquisitions, related integration costs and potential share repurchase 2022 Investments • Total Investments in business of ~$8M • Innovations & Projects ($3M) – spend related to automation, workforce optimization and roll out of Medalogix/Muse product • De Novos ($5M) – Expansion of de novo program 18

Environmental, Social, Governance (E.S.G.) Considerations 19

Environmental, Social, Governance (E.S.G.) Considerations Sustainable, high-quality, patient focused, home-based care model Environmental Social Governance • Amedisys strives to create an • Amedisys has a culture of compliance • Amedisys is dedicated to the organizational culture and climate in which starting with oversight from the Board of sustainability of our business and the every individual is valued, all team Directors and cascading down to the care communities in which we serve members have a sense of belonging with center level one another and to the organization and • Environmental health has a strong • Our Board of Directors operates several feel empowered to do their best work correlation with physical health sub-committees including: • Provider of Home Health and Hospice • Quality Committee • A greener fleet – newer vehicles, in services to frail, elderly patients in their • Compliance Committee circulation for a shorter time, optimize most preferred care location – their homes• Audit Committee fuel usage. Sophisticated scheduling • Compensation Committee • Highest quality Home Health company as • Nominating & Corporate practices reduce our clinicians’ driving measured by Quality of Patient Care Star Governance Committee time and fuel usage helping to minimize scores (4.33 Stars) our carbon footprint • Nominating and Corporate Governance • The Amedisys Foundation was formed to Committee oversees our strategy on provide support to our patients and • Virtual care centers, along with flexible corporate social responsibility, including employees. The Amedisys Foundation has working schedules and locations, have evaluating the impact of Company practices two funds: the Patients’ Special Needs created fewer emissions on communities and individuals, and Fund and the Amedisys Employees 1st develops and recommends to our Board of Fund. The Patients’ Special Needs Fund Directors for approval matters relating to provides financial assistance to our home the Company’s corporate social health, hospice and personal care patients responsibility and ESG considerations during a difficult time 20